LivaNova develops medical devices for cardiac surgery and neuromodulation. Its portfolio includes heart-lung machines and cardiopulmonary systems used in open-heart procedures, plus implantable vagus-nerve stimulation therapy for drug-resistant epilepsy and treatment-resistant depression. Hospitals and specialist clinics are the main customers; the dual focus on life-support hardware and implantable neurostimulation sets it apart from pure-play device or pharma peers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 352.5 | — | 27.2 | — |
| Q3 2025 | 357.8 | — | 26.8 | — |
| Q4 2025 | 360.9 | — | 30.9 | — |
| Q1 2026 | 362.3 | — | 22.3 | — |
| Q2 2026 | 390.6 | 10.8% | 108.6 | 299.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Grand Canyon Education, Inc. (LOPE), X-Energy, Inc. (XE), Heartflow, Inc. (HTFL), International Bancshares Corporation (IBOC), Kulicke and Soffa Industries, Inc. (KLIC), Liberty Global Ltd. (LBTYB)